Related Experiment Video

Updated: Jun 1, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

[The production of influenza vaccines from MDCK cell cultures]

Berthold Bruckhoff1

  • 1Novartis Vaccines, Emil-von-Behring-Str. 76, 35041 Marburg. Berthold.bruckhoff@novartis.com

Pharmazie in Unserer Zeit
|June 3, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Related Experiment Videos

Last Updated: Jun 1, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Articles linked to this work by shared authors, journal, and citation graph.

Immune Checkpoint Inhibitor-Induced Myelitis Presenting with "Hot Cord" Sign on 18F-FDG PET/CT: A Case Report.

Current medical imaging·2026

Isolated clival Langerhans cell histiocytosis in a pediatric patient: systematic review and illustrative case report.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2026

Investigating CD8 T Cell Exhaustion in Chronic LCMV Infection by Flow Cytometry.

Current protocols·2026

Localised cutaneous leishmaniasis in an immunosuppressed host: the role for adjuvant photodynamic therapy after incomplete amphotericin B response.

BMJ case reports·2026

Immunophenotyping of CD8+ T Cells in Classical Hodgkin Lymphoma Reveals a Shift Toward Intermediate Exhaustion Following PD-1 Blockade.

Cancer immunology research·2026

Mast Cells in Neuroimmune Interactions: Mechanisms, Pathophysiological Roles, and Therapeutic Implications.

Molecular neurobiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us